利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.025 秒)

    Model for studying the role of genes in tumor resistance to chemotherapy
    1.
    发明申请
    Model for studying the role of genes in tumor resistance to chemotherapy 审中-公开
    研究基因在肿瘤抗化疗中的作用模型

    公开(公告)号：US20060294604A1

    公开(公告)日：2006-12-28

    申请号：US10546055

    申请日：2004-02-17

    申请人： Jordan Fridman ,  Scott Lowe ,  Elisa de Stanchina ,  Hans Wendel ,  Jerry Pelletier

    发明人： Jordan Fridman ,  Scott Lowe ,  Elisa de Stanchina ,  Hans Wendel ,  Jerry Pelletier

    IPC分类号： A01K67/027 ,  C12N5/06 ,  C12N5/08 ,  C12N15/86

    CPC分类号： C12N15/86 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/0331 ,  A01K2267/0393 ,  C07K14/82 ,  C12N9/1205 ,  C12N15/8509 ,  C12N2740/14043 ,  G01N33/5011 ,  G01N33/502 ,  G01N33/574 ,  G01N2800/52

    摘要： The invention provides the components of in vivo and in vitro systems and methods which use them to study the effects of altered expression of a gene activity, such as the human akt, bcl-2, eIF4E or PTEN activities, on the descendants of stem cells that have been engineered to give rise to hematopoietic tumorigenic or tumor cells, such as lymphomas, with a high frequency. The present invention provides vectors, cells and mammals, and methods which in part depend on such products, useful for understanding tumorigenesis and its treatments, and in particular, for identifying and studying inhibitors and activators associated with tumor cell growth and growth inhibition, cell death through apoptotic pathways, and changes in apoptotic pathway components that affect drug sensitivity and resistance in tumorigenic cells. Methods for identifying molecular targets for drug screening, identifying interacting gene activities, for identifying therapeutic treatments and for identifying candidates for new therapeutic treatments are provided.

    摘要翻译： 本发明提供体内和体外系统和方法的组分，其使用它们来研究基因活性的表达改变如人类akt，bcl-2，eIF4E或PTEN活性对干细胞后代的影响 已被设计成以高频率引起造血致瘤性或肿瘤细胞如淋巴瘤。 本发明提供载体，细胞和哺乳动物，以及部分依赖于这些产物的方法，其可用于了解肿瘤发生及其治疗，特别是鉴定和研究与肿瘤细胞生长和生长抑制相关的抑制剂和激活剂，细胞死亡 通过细胞凋亡途径以及影响致瘤细胞中药物敏感性和抗性的凋亡途径成分的变化。 提供了用于鉴定用于药物筛选的分子靶标，鉴定相互作用的基因活性，用于鉴定治疗性治疗和鉴定新的治疗性治疗候选物的方法。

    Simian T-cell lymphotropic virus
    3.
    发明授权
    Simian T-cell lymphotropic virus 有权
    猿猴T细胞淋巴细胞病毒

    公开(公告)号：US08663968B2

    公开(公告)日：2014-03-04

    申请号：US12600995

    申请日：2008-05-20

    申请人： William M. Switzer ,  Walid Heneine ,  Thomas M. Folks ,  Nathan D. Wolfe ,  Donald S. Burke ,  David M. Sintasath

    发明人： William M. Switzer ,  Walid Heneine ,  Thomas M. Folks ,  Nathan D. Wolfe ,  Donald S. Burke ,  David M. Sintasath

    IPC分类号： C12N15/09 ,  C12N7/00 ,  A61K39/00

    CPC分类号： C07K14/005 ,  C07K16/1036 ,  C12N7/00 ,  C12N15/86 ,  C12N2740/14021 ,  C12N2740/14022 ,  C12N2740/14043 ,  G01N33/56983

    摘要： Disclosed are the simian T-cell lymphotropic virus type 3 subtype D (STLV-3 subtype D), isolated nucleic acid molecules encoding STLV-3 subtype D polypeptides, such as STLV-3 subtype D envelope, protease, polymerase, tax, rex, and capsid polypeptides, isolated polypeptides encoded by such nucleic acids. Methods are also disclosed for detecting STLV-3 subtype D, for example by detecting a STLV-3 subtype D nucleic acid or polypeptide in the sample. Accordingly, probes, primers, and antibodies for use in detecting STLV-3 subtype D nucleic acids or polypeptides are disclosed. Therapeutic compositions which included isolated nucleic acid molecules encoding a STLV-3 subtype D polypeptides or isolated polypeptides encoded by such nucleic acid molecules are also disclosed.

    摘要翻译： 公开了3型亚型T型细胞淋巴细胞病毒（STLV-3亚型D），编码STLV-3亚型D多肽的分离的核酸分子，例如STLV-3亚型D包膜，蛋白酶，聚合酶，tax，rex， 和衣壳多肽，由这种核酸编码的分离的多肽。 还公开了用于检测STLV-3亚型D的方法，例如通过检测样品中的STLV-3亚型D核酸或多肽。 因此，公开了用于检测STLV-3亚型D核酸或多肽的探针，引物和抗体。 还公开了包含编码STLV-3亚型D多肽的分离的核酸分子或由这种核酸分子编码的分离的多肽的治疗组合物。

    Methods utilizing mutant rev genes encoding transdominant repressors of HIV replication
    5.
    发明授权
    Methods utilizing mutant rev genes encoding transdominant repressors of HIV replication 失效
    使用编码HIV复制的横显性阻遏物的突变转录基因的方法

    公开(公告)号：US06251675B1

    公开(公告)日：2001-06-26

    申请号：US08459898

    申请日：1995-06-02

    申请人： Bryan R. Cullen

    发明人： Bryan R. Cullen

    IPC分类号： C12N1500

    CPC分类号： C07K14/005 ,  A61K38/00 ,  C07K16/1036 ,  C12N2740/10022 ,  C12N2740/10043 ,  C12N2740/14022 ,  C12N2740/14043 ,  C12N2740/16322 ,  G03C7/3013 ,  G03C7/36

    摘要： Transdominant repressors of viral gene phenotypic expression derived from the rev gene product of HIV-1 or the rex gene product of HTLV-1 and corresponding mutated genes are described, having the capability of repressing the Rev function in HIV-1 and/or the Rex function in HTLV-I and HTLV-II. Transient gene expression analysis of a series of missense and deletion mutants has been used. Sane of the mutants found repress both the Rev and the Rex function and are thus active in more than one viral species. Transdominant viral mutants represent a promising new class of anti-viral agents. Cellular expression of these transdominant inhibitors may be used in such therapeutic approaches as intracellular immunization in order to protect cells against the deleterious effects of viral, e.g. HIV-1 infection.

    摘要翻译： 描述了衍生自HIV-1的rev基因产物或HTLV-1的rex基因产物和相应的突变基因的病毒基因表型表达的显性阻遏物，其具有抑制HIV-1和/或Rex中的Rev功能的能力 功能在HTLV-I和HTLV-II。 已经使用了一系列错义和缺失突变体的瞬时基因表达分析。突变体的发现抑制了Rev和Rex功能，因此在多种病毒物种中活跃。显性病毒突变体代表了一种有希望的新类型的抗 - 病毒剂。 这些跨主导抑制剂的细胞表达可以用于诸如细胞内免疫的治疗方法中，以保护细胞免受病毒的有害影响，例如， HIV-1感染。

    PRIMATE T-LYMPHOTROPIC VIRUSES
    6.
    发明申请
    PRIMATE T-LYMPHOTROPIC VIRUSES 有权
    主要的T淋巴细菌病毒

    公开(公告)号：US20140080121A1

    公开(公告)日：2014-03-20

    申请号：US14032914

    申请日：2013-09-20

    申请人： Johns Hopkins University ,  The Government of the United States of America as represented by the Secretary of the Department of

    发明人： William M. Switzer ,  Walid Heneine ,  Thomas M. Folks ,  Nathan D. Wolfe ,  Donald S. Burke ,  Eitel Mpoudi Ngole

    IPC分类号： C12Q1/70

    CPC分类号： C12Q1/701 ,  A61K2039/5256 ,  C07K14/005 ,  C12N15/86 ,  C12N2740/14021 ,  C12N2740/14022 ,  C12N2740/14043 ,  C12Q1/70

    摘要： Disclosed are compositions and methods related to the isolation and identification of the primate T-lymphotropic viruses, HTLV-3 and HTLV-4. The diversity of HTLVs was investigated among central Africans reporting contact with NHP blood and body fluids through hunting, butchering, and keeping primate pets. Herein it is shown that this population is infected with a variety of HTLVs, including two retroviruses; HTLV-4 is the first member of a novel phylogenetic lineage that is distinct from all known HTLVs and STLVs; HTLV-3 falls within the genetic diversity of STLV-3, a group that has not previously been seen in humans. The present disclosure also relates to vectors and vaccines for use in humans against infection and disease. The disclosure further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-3 and HTLV-4 and related viruses.

    摘要翻译： 公开了与灵长动物T淋巴细胞病毒HTLV-3和HTLV-4的分离和鉴定有关的组合物和方法。 通过狩猎，屠宰和饲养灵长类宠物报告与NHP血液和体液接触的中非非洲人之间调查了HTLV的多样性。 在本文中，显示该群体感染了多种HTLV，包括两种逆转录病毒; HTLV-4是与所有已知的HTLV和STLV不同的新型系统发育谱系的第一个成员; HTLV-3属于STLV-3的遗传多样性，STLV-3是人类以前未见过的一种。 本公开还涉及用于人类抵抗感染和疾病的载体和疫苗。 本公开还涉及用于检测和诊断由HTLV-3和HTLV-4及相关病毒引起的感染和疾病的各种生物测定和试剂盒。

    Primate T-lymphotropic viruses
    7.
    发明授权
    Primate T-lymphotropic viruses 有权
    灵长类T淋巴细胞病毒

    公开(公告)号：US08541221B2

    公开(公告)日：2013-09-24

    申请号：US12829125

    申请日：2010-07-01

    申请人： William M. Switzer ,  Walid Heneine ,  Thomas M. Folks ,  Nathan D. Wolfe ,  Donald S. Burke ,  Eitel Mpoudi Ngole

    发明人： William M. Switzer ,  Walid Heneine ,  Thomas M. Folks ,  Nathan D. Wolfe ,  Donald S. Burke ,  Eitel Mpoudi Ngole

    IPC分类号： C12N7/00 ,  C12N7/04

    CPC分类号： C12Q1/701 ,  A61K2039/5256 ,  C07K14/005 ,  C12N15/86 ,  C12N2740/14021 ,  C12N2740/14022 ,  C12N2740/14043 ,  C12Q1/70

    摘要： Disclosed are compositions and methods related to the isolation and identification of the primate T-lymphotropic viruses, HTLV-3 and HTLV-4. The diversity of HTLVs was investigated among central Africans reporting contact with NHP blood and body fluids through hunting, butchering, and keeping primate pets. Herein it is shown that this population is infected with a variety of HTLVs, including two retroviruses; HTLV-4 is the first member of a novel phylogenetic lineage that is distinct from all known HTLVs and STLVs; HTLV-3 falls within the genetic diversity of STLV-3, a group that has not previously been seen in humans. The present disclosure also relates to vectors and vaccines for use in humans against infection and disease. The disclosure further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-3 and HTLV-4 and related viruses.

    摘要翻译： 公开了与灵长动物T淋巴细胞病毒HTLV-3和HTLV-4的分离和鉴定有关的组合物和方法。 通过狩猎，屠宰和饲养灵长类宠物报告与NHP血液和体液接触的中非非洲人之间调查了HTLV的多样性。 在本文中，显示该群体感染了多种HTLV，包括两种逆转录病毒; HTLV-4是与所有已知的HTLV和STLV不同的新型系统发育谱系的第一个成员; HTLV-3属于STLV-3的遗传多样性，STLV-3是人类以前未见过的一种。 本公开还涉及用于人类抵抗感染和疾病的载体和疫苗。 本公开还涉及用于检测和诊断由HTLV-3和HTLV-4及相关病毒引起的感染和疾病的各种生物测定和试剂盒。

    VACCINE AGAINST BOVINE LEUKEMIA VIRUS
    10.
    发明申请
    VACCINE AGAINST BOVINE LEUKEMIA VIRUS 审中-公开
    VACCINE反对BoVINE LEUKEMIA病毒

    公开(公告)号：US20160045593A1

    公开(公告)日：2016-02-18

    申请号：US14832863

    申请日：2015-08-21

    申请人： UNIVERSITÉ DE LIÈGE ,  INSTITUTO NACIONAL DE TECNOLOGÍA AGROPECUARIA

    发明人： Luc Willems ,  Karina Trono

    IPC分类号： A61K39/21 ,  C12N7/00

    CPC分类号： A61K39/21 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/552 ,  C07K14/005 ,  C12N7/00 ,  C12N2740/14021 ,  C12N2740/14022 ,  C12N2740/14034 ,  C12N2740/14043 ,  C12N2740/14062 ,  C12N2740/14071

    摘要： The invention relates to recombinant bovine leukemia viruses that have an attenuated phenotype and comprise a combination of at least two specific mutations. The invention also provides recombinant nucleic acids encoding such viruses, vectors comprising such nucleic acids, and host cells comprising such nucleic acids or vectors. The recombinant attenuated BLV viruses, recombinant nucleic acids, vectors and host cells allow for the preparation of improved vaccines, in particular vaccines suitable for the prophylactic treatment of BLV-associated diseases in subjects. The invention further provides methods for treating BLV-associated diseases in subjects and pharmaceutical compositions suitable for use in these methods.

    摘要翻译： 本发明涉及具有减毒表型并且包含至少两个特异性突变的组合的重组牛白血病病毒。 本发明还提供了编码这种病毒的重组核酸，包含这种核酸的载体和包含这种核酸或载体的宿主细胞。 重组减毒BLV病毒，重组核酸，载体和宿主细胞允许制备改进的疫苗，特别是适合预防性治疗受试者中与BLV相关的疾病的疫苗。 本发明还提供了治疗患有BLV相关疾病的方法和适用于这些方法的药物组合物。